These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 30455075

  • 21. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial.
    Deakin B, Suckling J, Barnes TRE, Byrne K, Chaudhry IB, Dazzan P, Drake RJ, Giordano A, Husain N, Jones PB, Joyce E, Knox E, Krynicki C, Lawrie SM, Lewis S, Lisiecka-Ford DM, Nikkheslat N, Pariante CM, Smallman R, Watson A, Williams SCR, Upthegrove R, Dunn G, BeneMin Study team.
    Lancet Psychiatry; 2018 Nov; 5(11):885-894. PubMed ID: 30322824
    [Abstract] [Full Text] [Related]

  • 22. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [Abstract] [Full Text] [Related]

  • 23. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
    Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M.
    J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
    [Abstract] [Full Text] [Related]

  • 24. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB.
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [Abstract] [Full Text] [Related]

  • 25. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 26. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 27. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [Abstract] [Full Text] [Related]

  • 29. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
    Lohr JB, Liu L, Caligiuri MP, Kash TP, May TA, Murphy JD, Ancoli-Israel S.
    Schizophr Res; 2013 Oct; 150(1):289-96. PubMed ID: 23938173
    [Abstract] [Full Text] [Related]

  • 30. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
    Nikbakhat MR, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A, Akhondzadeh S.
    Pharmacopsychiatry; 2016 Jul; 49(4):162-9. PubMed ID: 26902281
    [Abstract] [Full Text] [Related]

  • 31. The effects of glycine on auditory mismatch negativity in schizophrenia.
    Greenwood LM, Leung S, Michie PT, Green A, Nathan PJ, Fitzgerald P, Johnston P, Solowij N, Kulkarni J, Croft RJ.
    Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
    [Abstract] [Full Text] [Related]

  • 32. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
    Nasib LG, Sommer IE, Winter-van Rossum I, de Vries J, Gangadin SS, Oomen PP, Judge G, Blom RE, Luykx JJ, van Beveren NJM, Veen ND, Kroken RA, Johnsen EL.
    Trials; 2020 Jun 08; 21(1):492. PubMed ID: 32513294
    [Abstract] [Full Text] [Related]

  • 33. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct 08; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

  • 34. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia.
    Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G.
    J Neuropsychiatry Clin Neurosci; 2013 Oct 08; 25(1):E06-7. PubMed ID: 23487204
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S.
    J Child Adolesc Psychopharmacol; 2012 Oct 08; 22(5):327-42. PubMed ID: 23083020
    [Abstract] [Full Text] [Related]

  • 36. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.
    Pharmacopsychiatry; 2004 Nov 08; 37(6):270-8. PubMed ID: 15551193
    [Abstract] [Full Text] [Related]

  • 37. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.
    Eur Neuropsychopharmacol; 2014 Jun 08; 24(6):846-55. PubMed ID: 24636461
    [Abstract] [Full Text] [Related]

  • 38. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct 08; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 39. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B.
    J Clin Psychiatry; 2007 Mar 08; 68(3):368-79. PubMed ID: 17388705
    [Abstract] [Full Text] [Related]

  • 40. Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia.
    Chaves C, Marque CR, Maia-de-Oliveira JP, Wichert-Ana L, Ferrari TB, Santos AC, Araújo D, Machado-de-Sousa JP, Bressan RA, Elkis H, Crippa JA, Guimarães FS, Zuardi AW, Baker GB, Dursun SM, Hallak JE.
    Schizophr Res; 2015 Feb 08; 161(2-3):439-45. PubMed ID: 25497439
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.